TransMedics Group (TMDX) Set to Announce Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX - Get Free Report) will be issuing its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million during the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company's revenue was up 158.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.21) earnings per share. On average, analysts expect TransMedics Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TransMedics Group Stock Up 4.7 %

NASDAQ TMDX traded up $4.09 during trading on Tuesday, reaching $90.60. The company's stock had a trading volume of 590,256 shares, compared to its average volume of 690,071. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The stock has a market capitalization of $2.96 billion, a PE ratio of -112.35 and a beta of 1.99. The business has a 50-day moving average price of $82.85 and a 200-day moving average price of $73.74. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $99.63.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 4,000 shares of the company's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total value of $380,480.00. Following the sale, the chief executive officer now owns 74,087 shares of the company's stock, valued at approximately $7,047,155.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Waleed H. Hassanein sold 4,000 shares of the company's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 736 shares of the company's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now owns 14,375 shares in the company, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,078 shares of company stock valued at $9,972,971. 6.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of analyst reports. Oppenheimer lifted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Morgan Stanley boosted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, February 28th. Finally, Piper Sandler began coverage on shares of TransMedics Group in a report on Thursday, March 28th. They issued an "overweight" rating and a $95.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and an average target price of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.